parthenolide has been researched along with Sepsis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barochia, A; Cui, X; Eichacker, PQ; Li, X; Li, Y; Su, J | 1 |
| Hake, PW; Sheehan, M; Wong, HR; Zingarelli, B | 1 |
| Fink, MP | 1 |
| Groesdonk, HV; Senftleben, U | 1 |
1 review(s) available for parthenolide and Sepsis
| Article | Year |
|---|---|
Can we predict the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Humans; Mice; NF-kappa B; Pyruvates; Sepsis; Sesquiterpenes | 2009 |
3 other study(ies) available for parthenolide and Sepsis
| Article | Year |
|---|---|
Parthenolide improves systemic hemodynamics and decreases tissue leukosequestration in rats with polymicrobial sepsis.
Topics: Animals; Biopsy, Needle; Disease Models, Animal; Hemodynamics; Immunohistochemistry; Inflammation Mediators; Injections, Intraperitoneal; Male; Multiple Organ Failure; NF-kappa B; Random Allocation; Rats; Rats, Sprague-Dawley; Reference Values; Sepsis; Sesquiterpenes; Survival Rate; Treatment Outcome | 2003 |
Nuclear factor-kappaB: is it a therapeutic target for the adjuvant treatment of sepsis?
Topics: Animals; Chemotherapy, Adjuvant; Clinical Trials as Topic; Critical Care; Disease Models, Animal; Female; Humans; Male; Mice; NF-kappa B; Prognosis; Rats; Sepsis; Sesquiterpenes; Severity of Illness Index; Treatment Outcome | 2003 |
Modulation of inhibitor kappaB kinase/ nuclear factor kappaB signaling during critical illness: a double-edged sword.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Critical Care; Critical Illness; Disease Models, Animal; Humans; Inflammation; Multiple Organ Failure; NF-kappa B; Sepsis; Sesquiterpenes; Signal Transduction | 2004 |